Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; lactic acid; magnesium chloride hexahydrate; sodium carbonate hydrogen; sodium chloride - solution for haemofiltration - calcium chloride dihydrate 5.145 g / 1000 ml; magnesium chloride hexahydrate 2.033 g / 1000 ml; lactic acid 5.400 g / 1000 ml; sodium chloride 6.45 g / 1000 ml; sodium carbonate hydrogen 3.090 g / 1000 ml - combinations of electrolytes - combinations of electrolytes - as substitution solution in continuous haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis for acute renal failure.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sevoflurane, quantity: 250 ml - inhalation - excipient ingredients: - for induction and maintenance of general anaesthesia in adults and paediatric patients undergoing surgery.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.98 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 8.6 g/l; calcium chloride dihydrate, quantity: 330 mg/l; potassium chloride, quantity: 300 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - for restoring the loss of water and electrolytes as required by the clinical condition of the patient.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib baxter, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib baxter, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib baxter is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib baxter in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride; glucose; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.4 g/l; magnesium chloride 0.051 g/l; calcium chloride 0.184 g/l; glucose as monohydrate 15 g/l; glucose 13.6 g/l; lactic acid as sodium 4.5 g/l - isotonic solutions - for peritoneal dialysis including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride; glucose; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - glucose 38.6 g/l; lactic acid as sodium 4.5 g/l; glucose as monohydrate 42.5 g/l; magnesium chloride 0.051 g/l; sodium chloride 5.4 g/l; calcium chloride 0.184 g/l - isotonic solutions - indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride; glucose; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - lactic acid as sodium 4.5 g/l; sodium chloride 5.4 g/l; glucose 22.7 g/l; calcium chloride 0.184 g/l; magnesium chloride 0.051 g/l; glucose as monohydrate 25 g/l - indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; water for injections; sodium hydroxide; glacial acetic acid - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - flumazenil, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide; disodium edetate; glacial acetic acid; sodium chloride - flumazenil-baxter is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil-claris. not to be used in outpatients or short stay patients. not to be used as a diagnostic.